

CURRICULUM VITAE

Nome completo: Ana Barroso Abecasis (Abecasis A; Abecasis AB); Data de nascimento: 18 de Dezembro de 1978; Nacionalidade: Portuguesa; Morada profissional: Rua da Junqueira 100; 1349-008 Lisboa, Portugal; Telefone: +351 21 365 26 00 (ext. 269); E-mail: ana.abecasis@ihmt.unl.pt.

Orcid ID: [0000-0002-3903-5265](https://orcid.org/0000-0002-3903-5265)

ResearcherID: [B-6295-2009](https://pubs.rsos.royalsocietypublishing.org/author/B-6295-2009) (h-Index: 15, Citações: 706)

Google Scholar: <http://scholar.google.pt/citations?user=wZb3dUkAAAAJ&hl=pt-PT> (h-Index: 23, Citações: 1806)

ResearchGate: https://www.researchgate.net/profile/Ana_Abecasis2 (RG Score: 36.74, h-Index: 16, Citações: 1320)

GRAUS ACADÉMICOS

Grau: MD; Ano: 2014; Classificação Final: 16.5 (in 20); Universidade: Universidade Nova de Lisboa; Faculdade: Faculdade de Ciências Médicas; Área Científica: Medicina; Anos curriculares: 6; Título: Mestrado Integrado em Medicina.

Grau: PhD; Ano: 2009; Classificação Final: Não Aplicável; Universidade: KU Leuven (Bélgica); Tese: The impact of genetic diversity on HIV-1 molecular epidemiology and antiviral drug resistance; Orientador: Anne-Mieke Vandamme, Co-orientador: Ricardo Camacho; Área Científica: Ciências Médicas.

Grau: PharmD; Ano: 2002; Classificação Final: 15.3; Universidade: Universidade de Lisboa; Faculdade: Faculdade de Farmácia; Área Científica: Ciências Farmacêuticas; Anos curriculares: 6; Título: Licenciatura em Ciências Farmacêuticas.

POSIÇÃO ATUAL

Desde Novembro 2019, Diretora do Departamento de Saúde Pública Internacional e Bioestatística do Instituto de Higiene e Medicina Tropical (IHMT), , Universidade Nova de Lisboa, Lisboa, Portugal.

Desde Maio 2019, Professora Auxiliar no IHMT, Universidade Nova de Lisboa, Lisboa, Portugal.

ÁREAS DE ATIVIDADE CIENTÍFICA

Virologia, Microbiologia, Saúde Global, Resistência antiretroviral e antimicrobiana, Bioinformática, Evolução, Doenças Transmissíveis, Vírus de Evolução Rápida.

PRÉMIOS SELECIONADOS

Medalha de Honra L’Oreal Portugal FCT Unesco para as Mulheres na Ciência (2012).

EXPERIÊNCIA COMO ORIENTADORA CIENTÍFICA

Orientadora de 6 alunos de doutoramento (em curso), Co-orientadora de 5 alunos de doutoramento (1 já finalizada e 4 em curso), Orientadora/co-orientadora de 9 teses de mestrado (6 terminadas e 3 em curso), Orientadora de 4 investigadores de pós-doc (2 terminados e 2 em curso), Membro do júri de 4 teses de doutoramento.

PARTICIPAÇÃO EM PROJETOS DE INVESTIGAÇÃO

1 Projeto Europeu como Investigadora Principal, 3 Projetos Europeus como participante, 3 Projetos Nacionais como Investigadora Principal, 2 Projeto Nacionais como participante.

TRABALHOS PUBLICADOS

67 publicações em revistas internacionais indexadas; 2 Capítulos de livros, 10 apresentações orais por convite; 33 apresentações orais em painel em conferências nacionais e internacionais; 73 apresentações em poster em conferências nacionais e internacionais.

OUTROS

Revisora de artigos científicos para as revistas BMC Evolutionary Biology, BMC Infectious Diseases, Infections Genetics and Evolution, AIDS Research

and Human Retroviruses, grupo Plos. Membro de sociedades científicas internacionais: European Society for Translational Antiviral Research, European AIDS Clinical Society. Ordem dos Médicos portuguesa (cédula profissional nº 62843).

LISTA DE PUBLICAÇÕES

68 - Mavian C, Pond SK, Marini S, Magalis BR, Vandamme AM, Dellicour S, Scarpino SV, Houldcroft C, Villabona-Arenas J, Paisie TK, Trovão NS, Boucher C, Zhang Y, Scheuermann RH, Gascuel O, Lam TT, Suchard MA, **Abecasis A**, Wilkinson E, de Oliveira T, Bento AI, Schmidt HA, Martin D, Hadfield J, Faria N, Grubaugh ND, Neher RA, Baele G, Lemey P, Stadler T, Albert J, Crandall KA, Leitner T, Stamatakis A, Prosperi M, Salemi M. Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable. Proc Natl Acad Sci U S A. 2020 May 7. pii: 202007295. doi: 10.1073/pnas.2007295117. [Epub ahead of print] No abstract available. PMID:32381734

67 - Pimentel V, Pingarilho M, Alves D, Diogo I, Fernandes S, Miranda M, Pineda-Pena AC, Libin P, Martins MRO, Vandamme AM, Camacho R, Gomes P, **Abecasis A**. Molecular Epidemiology of HIV-1 Infected Migrants Followed up in Portugal: Trends between 2001-2017. Viruses. 2020 Feb 28;12(3).

66 - Pineda-Peña AC, Pingarilho M, Li G, Vrancken B, Libin P, Gomes P, Camacho RJ, Theys K, **Barroso Abecasis A**; Portuguese HIV-1 Resistance Study Group. Drivers of HIV-1 transmission: The Portuguese case. PLoS One. 2019 Sep 30;14(9):e0218226.

65 - Theys K, Libin PJK, Van Laethem K, **Abecasis AB**. An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors. Antimicrob Agents Chemother. 2019 Jul 25;63(8).

64 – Pimentel V, Afonso R, Nunes M, Vieira ML, Bravo-Barriga D, Frontera E, Martinez M, Pereira A, Maia C, Paiva-Cardoso MDN, Freitas FB, **Abecasis AB**, Parreira R. Geographic dispersal and genetic diversity of tick-borne phleboviruses (Phenuiviridae, Phlebovirus) as revealed by the analysis of L segment sequences. Ticks Tick Borne Dis. 2019 Jun;10(4):942-948.

63 – Salgueiro P, Serrano C, Gomes B, Alves J, Sousa CA, **Abecasis A**, Pinto J. Phylogeography and invasion history of *Aedes aegypti*, the Dengue and Zika mosquito vector in Cape Verde islands (West Africa). Evol Appl. 2019 Aug 3;12(9):1797-1811. doi: 10.1111/eva.12834.

62 - Araújo PMM, Carvalho A, Pingarilho M; BEST-HOPE study group, **Abecasis AB**, Osório NS. Characterization of a large cluster of HIV-1 A1 infections detected in Portugal and connected to several Western European countries. Sci Rep. 2019 May 10;9(1):7223. doi: 10.1038/s41598-019-43420-2.

61 - Fonseca V, Libin PJK, Theys K, Faria NR, Nunes MRT, Restovic MI, Freire M, Giovanetti M, Cuypers L, Nowé A, **Abecasis A**, Deforche K, Santiago GA, Siqueira IC, San EJ, Machado

KCB, Azevedo V, Filippis AMB, Cunha RVD, Pybus OG, Vandamme AM, Alcantara LCJ, de Oliveira T. A computational method for the identification of Dengue, Zika and Chikungunya virus species and genotypes. *PLoS Negl Trop Dis*. 2019 May 8;13(5):e0007231.

60 – Vasylyeva TI, du Plessis L, Pineda-Peña AC, Kühnert D, Lemey P, Vandamme AM, Gomes P, Camacho RJ, Pybus OG, **Abecasis AB**, Faria NR. Tracing the Impact of Public Health Interventions on HIV-1 Transmission in Portugal Using Molecular Epidemiology. *J Infect Dis*. 2019 Jun 19;220(2):233-243.

59 - Tavares AM, Garcia AC, Gama A, **Abecasis AB**, Viveiros M, Dias S. Tuberculosis care for migrant patients in Portugal: a mixed methods study with primary healthcare providers. *BMC Health Serv Res*. 2019 Apr 18;19(1):233.

58 - Libin P, Deforche K, **Abecasis AB**, Theys K. VIRULIGN: fast codon-correct alignment and annotation of viral genomes. *Bioinformatics*. 2018 Oct 8. [IF 2018 =5.48]

57 - Ezeonwumelu I, Bártolo I, Martin F, **Abecasis A**, Campos T, Romero-Severson EO, Leitner T, Taveira N. Accidental Father-to-Son HIV-1 Transmission During the Seroconversion Period. *AIDS Res Hum Retroviruses*. 2018 Oct;34(10):857-862. [IF 2018 =1.94]

56 - Correia V, **Abecasis AB**, Rebelo-de-Andrade H. Molecular footprints of selective pressure in the neuraminidase gene of currently circulating human influenza subtypes and lineages. *Virology*. 2018 Sep;522:122-130. [IF 2018 =3.37]

55 - Grant JC, González-Beiras C, Amick KM, Fortney KR, Gangaiah D, Humphreys TL, Mitjà O, **Abecasis A**, Spinola SM. Multiple Class I and Class II *Haemophilus ducreyi* Strains Cause Cutaneous Ulcers in Children on an Endemic Island. *Clin Infect Dis*. 2018 Nov 13;67(11):1768-1774. [IF 2018 =9.12]

54 - Pineda-Peña AC, Theys K, Stylianou DC, Demetriades I; SPREAD/ESAR Program, **Abecasis AB**, Kostrikis LG. HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012. *Sci Rep*. 2018 Jan 26;8(1):1702. [IF 2018 =4.12]

53- Theys K, Libin P, Pineda-Peña AC, Nowé A, Vandamme AM, **Abecasis AB**. The impact of HIV-1 within-host evolution on transmission dynamics. *Curr Opin Virol*. 2018 Feb; 28:92-101. [IF 2018 =5.64]

52 - **Abecasis AB**, Pingarilho M, Vandamme AM. Phylogenetic analysis as a forensic tool in HIV transmission investigations. *AIDS*. 2018 Mar 13;32(5):543-554. [IF 2018 =4.91]

51 - Romero-Severson EO, Bulla I, Hengartner N, Bártolo I, **Abecasis A**, Azevedo-Pereira JM, Taveira N, Leitner T. Donor-Recipient Identification in Para- and Polyphyletic Trees Under Alternative HIV-1 Transmission Hypotheses Using Approximate Bayesian Computation. *Genetics*. 2017 Nov;207(3):1089-1101. [IF 2017 =4.08]

50 - Paraschiv S, Banica L, Nicolae I, Niculescu I, Abagiu A, Jipa R, Pineda-Peña AC, Pingarilho M, Neaga E, Theys K, Libin P, Otelea D, **Abecasis A**. Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users. *PLoS One*. 2017 Oct 9;12(10):e0185866. [IF 2017 =2.77]

49 - Tavares AM, Fronteira I, Couto I, Machado D, Viveiros M, **Abecasis AB**, Dias S. HIV and tuberculosis co-infection among migrants in Europe: A systematic review on the prevalence, incidence and mortality. *PLoS One*. 2017 Sep 28;12(9):e0185526. [IF 2017 =2.77]

48 - Theys K, Libin P, Dallmeier K, Pineda-Peña A-C, Anne-Mieke Vandamme A-M, Cuypers L, **Abecasis AB**. Zika genomics in urgent need for standardized and curated reference sequences. *PLoS Pathog*. 2017 Sep 7;13(9). [IF 2017 =6.16]

47 - Gama A, **Abecasis A**, Pingarilho M, Mendão L, Martins MO, Barros H, Dias S. Cruising Venues as a Context for HIV Risky Behavior Among Men Who Have Sex With Men. *Arch Sex Behav*. 2017 Maio;46(4):1061-1068. [IF 2017 =3.22]

46 - Pineda-Peña AC, Varanda J, Sousa JD, Theys K, Bártolo I, Leitner T, Taveira N, Vandamme AM, **Abecasis AB**. On the contribution of Angola to the initial spread of HIV-1. *Infect Genet Evol*. 2016 Dec;46:219-222. [IF 2016 =2.89]

45 - Theys K, Van Laethem K, Gomes P, Baele G, Pineda-Peña AC, Vandamme AM, Camacho RJ, **Abecasis AB**. Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations. *AIDS Res Hum Retroviruses*. 2016 Maio;32(5):427-33. [IF 2016 =2.10]

44 - Winand R, Theys K, Eusébio M, Aerts J, Camacho RJ, Gomes P, Suchard MA, Vandamme AM, **Abecasis AB**; Portuguese HIV-1 Resistance Study Group. Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals. *AIDS*. 2015 Sep 24;29(15):2045-52. [IF 2015 =4.41]

43 - Theys K, **Abecasis A**, Libin P, Gomes P, Cabanas J, Camacho RJ, Van Laethem K. Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure. *J Clin Virol*. 2015 Sep;70:120-7. [IF 2015 =2.65]

42 - Carapeta S, do Bem B, McGuinness J, Esteves A, **Abecasis A**, Lopes Â, de Matos AP, Piedade J, de Almeida AP, Parreira R. Negevirus found in multiple species of mosquitoes from southern Portugal: Isolation, genetic diversity, and replication in insect cell culture. *Virology*. 2015 Sep;483:318-28. [IF 2015 =3.2]

41 - **Abecasis AB**, Van Laethem K, Theys K. Lack of evidence for the selection of E138 mutations by first-generation NNRTIs in patients infected with HIV-1 non-B subtypes: a comment on Crawford et al. *AIDS*. 2015 Maio 15;29(8):987-8. [IF 2015 = 4.41]

40 - Lunar MM, Vandamme A-M, Tomazic J, Karner P, Vovko TD, Pecavar B, Volcansek G, Poljak M, **Abecasis AB**. Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe. *BMC Infect Dis*. 2015 Feb 15;15(1):65. [IF 2015 = 2.69]

39 - Frentz D, Van de Vijver DA, **Abecasis AB**, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Asjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnernborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. *BMC Infect Dis*. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407. [IF 2014 = 2.62]

38 - Frentz D, van de Vijver D, **Abecasis A**, Albert J, Hamouda O, Jørgensen L, Kücherer C, Struck D, Schmit JC, Vercauteren J, Asjö B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnernborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher C, Programme AW. Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. *PLoS One*. 2014 Apr 10;9(4):e94495. doi: 10.1371/journal.pone.0094495. [IF 2014 = 3.23]

37 - Cavaco-Silva J, **Abecasis A**, Miranda AC, Poças J, Narciso J, Aguas MJ, Maltez F, Almeida I, Germano I, Diniz A, Gonçalves Mde F, Gomes P, Cunha C, Camacho RJ; Portuguese HIV-2 Resistance Study Group. HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen. *PLoS One*. 2014 Mar 28;9(3):e92747. doi: 10.1371/journal.pone.0092747. [IF 2014 = 3.23]

36 - Foster GM, Ambrose JC, Hué S, Delpech VC, Fearnhill E, **Abecasis AB**, Leigh Brown AJ, Geretti AM; UK HIV Drug Resistance Database. Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. *PLoS One*. 2014 Jan 15;9(1):e83337. doi: 10.1371/journal.pone.0083337. [IF 2014 = 3.23]

35 - Bartha I, Assel M, Sloot PM, Zazzi M, Torti C, Schülter E, Luca AD, Sönnernborg A, **Abecasis AB**, Van Laethem K, Rosi A, Svärd J, Paredes R, van de Vijver DA, Vandamme AM, Müller V. Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. *BMC Infect Dis*. 2013 Nov 12;13:537. doi: 10.1186/1471-2334-13-537. [IF 2013 = 2.56]

34 - Soares P, Alves RJ, **Abecasis AB**, Penha-Gonçalves C, Gomes MG, Pereira-Leal JB. inTB - a data integration platform for molecular and clinical epidemiological analysis of tuberculosis. *BMC Bioinformatics*. 2013 Aug 30;14(1):264. [IF 2013 = 2.67]

33 - Ferreira DD, Cook S, Lopes A, de Matos AP, Esteves A, **Abecasis A**, de Almeida AP, Piedade J, Parreira R. Characterization of an insect-specific flavivirus (OCFV_{PT}) co-isolated from *Ochlerotatus caspius* collected in southern Portugal along with a putative new Negev-like virus. *Virus Genes*. 2013 Jul 23. [IF 2013 = 1.84]

32 - Pineda-Peña AC, Faria NR, Imbrechts S, Libin P, **Abecasis AB**, Deforche K, Gómez-López A, Camacho RJ, de Oliveira T, Vandamme AM. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. *Infect Genet Evol*. 2013 Maio 7. [IF 2013 = 3.26]

31 - **Abecasis AB**, Serrano M, Alves R, Quintais L, Pereira-Leal JB, Henriques AO. A genomic signature and the identification of new sporulation genes. *J Bacteriol*. 2013 Maio; 195(9):2101-15. Epub 2013 Fev 8. [IF 2013 = 2.69]

30 - Frenzt D, Wensing AM, Albert J, Paraskevis D, **Abecasis AB**, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, De Wit S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnernborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA, Van de Vijver DA; SPREAD Programme. Limited cross-border infections in patients newly diagnosed with HIV in Europe. *Retrovirology*. 2013 Apr 3;10:36. [IF 2013 = 4.77]

29 - Theys K, **Abecasis AB**, Vandamme AM. HIV-1 drug resistance: where do polymorphisms fit in? *Future Microbiol*. 2013 Mar;8(3):303-6. [IF 2013 = 3.82]

28 - Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, Torti C, Schülter E, Clotet B, Sönnernborg A, De Luca A, Grossman Z, Struck D, Vandamme A-M and **Abecasis AB**. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. *Antimicrobial Agents and Chemotherapy*. 2013 Fev;57(2):1053-6. [IF 2013 = 4.45]

27 - **Abecasis AB**, Wensing AMJ, Paraskevis D, Vercauteren J, Theys K, Van de Vijver DAMC, Albert J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit J-C, Sönnernborg A, Stanekova D, Stanojevic M, Struck D, Boucher CAB and Vandamme A-M on behalf of the SPREAD Programme. HIV-1 subtype distribution and its demographic determinants suggest highly compartmentalized epidemic in newly diagnosed patients in Europe. *Retrovirology*. 2013 Jan 14;10:7. [IF 2012 = 4.77]

26 - Nunes MR, Faria NR, Vasconcelos HB, Medeiros DB, de Lima CP, Carvalho VL, Pinto da Silva EV, Cardoso JF, Sousa Jr. EC, Barbosa Nunes KN, **Abecasis AB**, Suchard MA, Lemey P, Vasconcelos PF. Phylogeography of Dengue Virus Serotype 4, Brazil, 2010–2011. *Emerging Infectious Diseases*. 2012 Nov;18(11):1858-64. [IF 2012 = 5.99]

25 - Theys K, Snoeck J, Vercauteren J, **Abecasis AB**, Vandamme A-M and Camacho R on behalf of the Portuguese HIV-1 Resistance Study Group. Decreasing population selection rates of resistance mutation 1 K65R over calendar year in HIV-1 combination therapy including tenofovir. *Journal of Antimicrobial Chemotherapy*. 2012 Sep 30. [IF 2012 = 5.34]

24 - Lunar MM, Zidovec Lepej S, **Abecasis AB**, Tomažič J, Vidmar L, Karner P, Vovko TD, Pečavar B, Maver PJ, Seme K, Poljak M. Prevalence of HIV Type 1 Transmitted Drug Resistance in Slovenia: 2005-2010. *AIDS Res Hum Retroviruses*. 2012 Aug 29. [IF 2012 = 2.71]

23 - Santos AF, Tebit DM, Lalonde MS, **Abecasis AB**, Ratcliff A, Camacho RJ, Diaz RS, Herchenröder O, Soares MA, Arts EJ. The role of natural polymorphisms in HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility. *Antimicrob Agents Chemother*. 2012 Feb 13. [IF 2012 = 4.57]

22 - Bártolo I, **Abecasis AB**, Borrego P, Barroso H, McCutchan F, Gomes P, Camacho R and Taveira N. Origin and Epidemiological History of HIV-1 CRF14_BG. *Plos One*. 2011;6(9):e24130. Epub 2011 Sep 28. [IF 2011 = 4.09]

21 - Faria NR, Suchard MA, **Abecasis A**, Sousa JD, Ndembi N, Bonfim I, Camacho RJ, Vandamme AM, Lemey P. Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. *Infect Genet Evol*. 2012 Mar;12(2):453-60. Epub 2011 Maio 4. [IF 2011 = 3.13]

20 - **Abecasis AB**, Geretti AM, Albert J, Power L, Wait M, Vandamme AM. Science in court: the myth of HIV fingerprinting. *Lancet Infect Dis*. 2011 Feb; 11(2):78-9. [IF 2011 = 17.39]

19 - **Abecasis, AB**; Martins, A; Costa, I; Carvalho, AP; Diogo, I; Gomes, P; Camacho, RJ. Molecular epidemiological analysis of paired pol/env sequences from portuguese HIV-1 patients. *AIDS Res Hum Retroviruses*. 2011 Feb 16. [IF 2011 = 2.25]

18 - **Abecasis AB**. and Müller V. The dynamics of transmitted HIV-1 drug resistance - the San Francisco model. *AIDS Reviews*. 2010 Apr-Jun; 12(2): 122. [IF 2010 = 4.79]

17 - **Abecasis AB**, Wang Y, Libin P, Imbrechts S, de Oliveira T, Camacho RJ, Vandamme AM. Comparative performance of the REGA subtyping tool version 2 versus version 1. *Infect Genet Evol*. 2010 Apr;10(3):380-5. [IF 2010 = 3.09]

16 - **Abecasis AB**, Vandamme A-M, Lemey P. Quantifying differences in the tempo of HIV-1 subtype evolution. *Journal of Virology*. 2009 Dec;83(24):12917-24. Epub 2009 Sep 30. [IF 2009 = 5.15]

15 - Bártolo I, Casanovas J, Bastos R, Rocha C, **Abecasis AB**, Folgosa E, Mondlane J, Manuel R, Taveira N. HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique. *J Acquir Immune Defic Syndr*. 2009 Jul 1;51(3):323-31. [IF 2009 = 4.21]

14 - Palma AC, **Abecasis AB**, Vercauteren J, Carvalho AP, Cabanas J, Vandamme AM, Camacho RJ. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. *Infect Genet Evol.* 2010 Apr;10(3):380-5. [IF 2010 = 3.09]

13 - Santos AF, **Abecasis AB**, Vandamme AM, Camacho RJ, Soares MA. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. *Journal of Antimicrobial Chemotherapy.* 2009 Mar;63(3):593-9. Epub 2009 Jan 10. [IF 2009 = 4.35]

12 - Theys K, Vercauteren J, **Abecasis AB**, Libin P, Deforche K, Vandamme AM, Camacho R. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. *Infections Genetics and Evolution.* Jul; 9(4):683-8. Epub 2008 Nov 6. [IF 2008 = 2.79]

11 - Gonzalez L, Santos A, **Abecasis A**, VanLaethem K, Soares E, Deforche K, Tanuri A, Camacho R, Vandamme A-M, Soares M. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. *Journal of Antimicrobial Chemotherapy.* 2008 Jun; 61(6):1201-4. Epub 2008 Mar 20. [IF 2008 = 4.33]

10 - Ho YS, **Abecasis AB**, Theys K, Deforche K, Dwyer DE, Charleston M, Vandamme A-M, Saxena NK. HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartments. *Virology Journal.* 2008 Jan 23;5:14. [IF 2008 = 1.88]

9 – **Abecasis AB**, Vandamme A-M. Denial of expert opinion in HIV court cases. *AIDS Reviews*; 2007; Vol. 9; iss. 4; pp. 254 – 254.

8 - **Abecasis AB**, Lemey P, Vidal N, de Oliveira T, Peeters M, Camacho R, Shapiro B, Rambaut A, Vandamme A-M. Recombination is confounding the early evolutionary history of HIV-1: subtype G is a circulating recombinant form. *Journal of Virology* 2007. *J Virol.* 2007 Aug; 81(16):8543-51. Epub 2007 Jun 6. [IF 2007 = 5.33]

7 - Katzenstein DA, Camacho RJ, **Abecasis AB**, Vandamme A-M and Shafer RW for the HIV-1 Non-Subtype B Working Group. Authors' Reply to: Role for Geographical Location and Founder Effects in Describing HIV-1 Subtype-Specific Polymorphisms. *Plos Medicine* 2006. Published online 4 Dec 2006. [IF 2006 = 13.75]

6 - **Abecasis AB**, Deforche K, Bachelier LT, McKenna P, Carvalho AP, Gomes P, Vandamme A-M, Camacho R. Investigation of baseline susceptibility to PIs in HIV-1 subtypes C, F, G and CRF02_AG. *Antiviral Therapy* 2006. 11(5):581-9. [IF 2006 = 4.98]

5 - Gomes P, Palma AC, Cabanas J, **Abecasis AB**, Carvalho AP, Ziermann R, Diogo I, Gonçalves F, Lobo CS, Camacho R. Comparison of the COBAS TAQMANTM HIV-1 HPS with VERSANT HIV-1 RNA

3.0 Assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes. *Journal of Virological Methods* 2006. Aug; 135(2):223-8. [IF 2006 = 2.10]

4 - **Abecasis AB**, Deforche K, Snoeck J, Bachelier LT, Mc Kenna P, Ana Patrícia Carvalho, Gomes P, Camacho RJ, Vandamme A-M. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. *AIDS* 2005 Nov 4; 19(16):1799-806. [IF 2005 = 5.84]

3 - **Abecasis A**, Paraskevis D, Epalanga M, Fonseca M, Burity F, Bartolomeu J, Carvalho A P, Gomes P, Vandamme A-M, Camacho R. HIV-1 genetic variants circulation in the North of Angola. *Infect Genet Evol.* 2005 Apr; 5(3):231-7. [IF 2007 = 2.41]

2 - Paraskevis D, Deforche K, **Abecasis A**, Camacho R, Vandamme A-M. Analysis of complex HIV-1 intersubtype recombinants: utilization of Bayesian scanning method. *Infect Genet Evol.* 2005 Apr;5(3):219-24. [IF 2007 = 2.41]

1 - Gomes P, **Abecasis A**, Almeida M, Mansinho K, Camacho R. Transmission of HIV-2. *Lancet Infectious Diseases.* 2003 Nov; 3(11):683-4. [IF 2004 = 10.79]

Lisboa, 12 de Maio de 2020,



(Ana Abecasis)